NLRP3 Candidate Screen — Evidence and Falsification Gates¶
Decision this page owns¶
This page asks which exact materials deserve a gout-relevant, exposure-matched human-cell experiment. It does not rank compounds across heterogeneous assays, select a production chassis, or define a treatment stack.
An NLRP3 candidate can enter through several legitimate evidence routes:
- a direct NLRP3 or inflammasome-assembly measurement;
- a functional MSU/macrophage readout;
- a gout-relevant animal model;
- a human gout study;
- or a grounded mechanism conjecture with a discriminating experiment.
Those routes answer different questions. They are not interchangeable tiers on one potency ladder.
Evidence contract¶
- Direct NLRP3 inhibitor requires a source-verified direct binding or inhibition measurement against NLRP3 in a named assay.
- NLRP3 pathway modulator means the source measured a functional inflammasome output or an upstream/downstream node.
- Animal Model does not become human evidence through dose scaling.
- Database retrieval is a discovery aid. Non-retrieval is not biological absence.
- Values from different species, cell types, stimuli, endpoints, and assay formats must not be divided into a “species gap” or cross-compound potency ratio.
- Food occurrence and microbial titer affect sourcing only after biological identity, exposure, function, and safety are qualified.
Current candidate set¶
| Candidate | Grounded evidence | What remains unproven | Cheapest discriminating gate |
|---|---|---|---|
| Dapansutrile | Published Phase 2a gout study plus source-specific cellular NLRP3 assays (Clinical Trial + In Vitro; PMID 33005902) | Transfer of its assay values to another compound, material, or dose | Use as a clinical/mechanistic comparator; reverify the exact primary assay before fixing a control concentration |
| Oridonin | Reported covalent NLRP3/NEK7 mechanism and experimental inflammasome effects (In Vitro + Animal Model; PMID 29959312) | Human gout efficacy and exposure; comparability of biochemical and cellular potency | Exact-material human macrophage MSU assay with NLRP3/NEK7, inflammasome, exposure, and viability readouts |
| Sulforaphane | Direct MSU-relevant animal and macrophage studies (Animal Model + In Vitro; PMIDs 29340626 and 26269198) | Human exposure, mechanism attribution across preparations, and gout efficacy | Preparation-qualified human macrophage MSU assay plus measured sulforaphane exposure |
| Theaflavins | Exact study materials changed NLRP3-related readouts in MSU-stimulated cells and an MSU animal model (In Vitro + Animal Model; PMID 37221235) | Material equivalence, human exposure, causal target attribution, and transport effects | Composition-qualified material panel with MSU, transporter, exposure, and viability readouts |
| Beta-caryophyllene | Oral exact-material activity in an MSU rat model with CB2/NLRP3-pathway readouts (Animal Model; PMID 33967792) | Human-cell activity, CB2 dependence, and delivered exposure | CB2-on/off human macrophage MSU assay with free-exposure measurement |
| Limonene | A cited rat MSU/hyperuricemia study supplies an animal lead (Animal Model; PMID 41515190) | Human-cell activity, exact mechanism, and exposure transfer | Human macrophage MSU assay plus direct exposure and target-engagement measurements |
| Quercetin | A source-pinned 5-LOX primary assay supplies one mechanism-specific lead (In Vitro; PMID 2066989); inherited inflammasome and animal claims require rehydration | Whether either mechanism matters at achievable gout-relevant exposure | Rehydrate the inflammasome source, then use a human macrophage/neutrophil experiment that measures inflammasome and LTB4 branches separately |
| Curcumin and EGCG | Unranked material-specific retrieval leads; this page does not retain a primary-source-pinned gout or NLRP3 evidence tier | Exact material, model, free exposure, transporter effects, and causal target | Rehydrate each exact material before comparing it at measured exposure; keep NLRP3, proteasome/NF-κB, ABCG2, and safety readouts separate |
| Carnosine | Unranked hyperuricemia and inflammatory-pathway retrieval lead; the inherited animal record is not rehydrated here | Exact material, model, direct human-cell MSU activity, compartment exposure, and carnosinase constraint | Rehydrate the animal record before running separate exposure-matched urate-handling and macrophage gates |
| Lactoferrin | Exact-material biochemical and adjacent radiation-injury pyroptosis observations (In Vitro + Animal Model; PMID 41524100) | Direct MSU activity, relevant-compartment exposure, material transfer, and fungal-product equivalence | Material-qualified human MSU assay; production identity and retained function are independent gates |
| KPV | PepT1-dependent uptake and NF-κB-related anti-inflammatory effects in intestinal epithelial and Jurkat-cell systems (In Vitro; PMID 18061177) | Direct MSU, synovial, macrophage-NLRP3, human exposure, and gout efficacy | PepT1-on/off human macrophage MSU assay measuring intracellular KPV, priming, inflammasome output, and viability |
| SPMs | Exact RvD1 and MaR1 materials have direct MSU animal evidence through different reported routes (Animal Model; PMIDs 35716378 and 37996809) | Human exposure, receptor contribution, class transfer, and combination value | Exact-mediator MSU comparison with receptor perturbation, exposure, resolution kinetics, and host-defense readouts |
| Salidroside | One bibliographic record supplies an MSU animal-study retrieval lead (PMID 30265377); the primary study is not rehydrated here | Exact material, animal-model result, human-cell activity, mechanism attribution, exposure, and human efficacy | Rehydrate the primary study before assigning an evidence tier, then decide whether an exact-material human MSU assay is justified |
The table preserves leads without producing a winner. It is not a coverage claim: a named row is not a validated chokepoint, and an absent row is not evidence of biological absence. A negative result kills only the tested material, exposure, compartment, timing, and readout.
Cross-system translation experiment¶
Separate dapansutrile studies report different cellular potency values in different species and assay systems. Because species, cell type, stimulus, timing, and protocol change together, their numerical ratio does not isolate species.
A useful bridge is a matched experiment:
- use the same compound lot and free-exposure measurement;
- compare mouse and human macrophages under the same priming and activation sequence;
- measure NLRP3 assembly, ASC specks, caspase-1, mature IL-1β, GSDMD, and viability;
- estimate the species effect only within that controlled design;
- repeat for a candidate only when the result would change its advancement decision.
Research sequence¶
- Rehydrate the evidence. Verify exact material, primary source, model, exposure, and readout.
- Run the human-cell gate. Measure mechanism-proximal effects and viability under MSU challenge.
- Close exposure. Show that the active free concentration is achievable in the intended compartment.
- Test attribution. Use receptor, target, or pathway perturbation rather than downstream markers alone.
- Compare sourcing. Only now compare purified, dietary, standardized-extract, or engineered routes.
- Test combinations last. Require individual-arm effects and a prespecified interaction model.
ChEMBL boundary¶
The current compact ChEMBL receipt does not retain immutable raw responses and every exact request parameter. It can locate candidate records but cannot support exhaustive counts, zero-entry claims, cross-assay rankings, or a complete target census. Inspect the named primary assay before using any retrieved value. See ChEMBL cross-check.
Current decision¶
- Advance exact materials through source rehydration and matched human-cell gates.
- Retain mechanistically useful leads even when direct gout evidence is absent.
- Do not infer a preferred compound, dose, route, stack, production host, or clinical program from this screen.
Research-stage analysis. Phase 0 — Research & Design.